3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.05
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.49%-4.33%+31.99%+75.23% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
-1.01%-0.89%+29.58%+14.29% 25.8B
+0.07%-0.46%+23.08%-16.47% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
-1.23%-2.19%-7.89%+517.41% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
Average -0.27%+0.74%+42.85%+177.48% 30.86B
Weighted average by Cap. -0.01%+0.11%+37.98%+140.14%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!